Drugs / FLUORESCEIN LISICOL
FLUORESCEIN LISICOL
also known as
NRL972 · Cholyl-Lysyl-Fluorescein · Cholyl-lysl-fluorescein · Fluoresceina lisicol · Fluoresceine lisicol
Trials 8 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT00896597 | Apr → Dec 2009 | cirrhosis of liver | Norgine | Completed | No outcome recorded |
| Phase 1 | NCT00857480 | Jun → Aug 2006 | cirrhosis of liver | Norgine | Completed | No outcome recorded |
| Phase 1 | NCT00856752 | Jun → Jul 2006 | — | Norgine | Completed | No outcome recorded |
| Phase 1 | NCT00856713 | Mar → Aug 2006 | cirrhosis of liver | Norgine | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00856869 | Aug 2004 → Feb 2005 | cirrhosis of liver, metabolic dysfunction-associated steatohepatitis | Norgine | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT00915057 | Mar 2009 | viral hepatitis | Norgine | Completed | No outcome recorded |
| Phase 2 | NCT00794716 | Jun 2008 → Mar 2010 | NAFLD1, metabolic dysfunction-associated steatohepatitis | Norgine | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT00794482 | Mar 2008 → Jun 2009 | cirrhosis of liver | Norgine | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FLUORESCEIN LISICOL | ChEMBL registry synonym — accepted as the source's own label CHEMBL2107751 ↗ |
| Known as | Cholyl-lysl-fluorescein | ChEMBL registry synonym — accepted as the source's own label CHEMBL2107751 ↗ |
| Known as | Cholyl-Lysyl-Fluorescein | “A Single-Centre, Open, Controlled, Randomised Cross-Over Study in Healthy Male and Female Volunteers to Evaluate the Pharmacokinetics of Cholyl-Lysyl-Fluorescein (NRL972) in...” NCT00856752 ↗3“A Study in Healthy Volunteers and Patients With Liver Cirrhosis to Assess the Effects of Age, Gender, and Stable Liver Disease on the Clearance of Cholyl-Lysyl-Fluorescein...” NCT00856713 ↗ “pharmacokinetics of Cholyl-Lysyl-Fluorescein (NRL972) in the Presence of Medication-Induced Changes in Cytochrome P450 or Biliary Transporter Proteins” NCT00857480 ↗ “Cholyl-lysyl-fluorescein (NRL972)” NCT00915057 ↗ |
| Known as | Fluoresceina lisicol | ChEMBL registry synonym — accepted as the source's own label CHEMBL2107751 ↗ |
| Known as | Fluoresceine lisicol | ChEMBL registry synonym — accepted as the source's own label CHEMBL2107751 ↗ |
| Known as | NRL972 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00856869 ↗ |
| Modality | Diagnostic / imaging agent | “as an in-Vivo Marker of Liver Function in Man” NCT00856713 ↗ |
| Route | Intravenous | “administered intravenously” NCT00794482 ↗ |